menu
    • menu

    Company profile for Eyevensys

    NEW Drugs in Dev: 5
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eyevensys is a private biotechnology company developing a novel approach in the treatment of major ophthalmic diseases. We create a bio therapeutics factory in the eye to allow safe local sustained production of therapeutic proteins, an approach that can address a wide range of ophthalmic diseases. Our approach is based on Eyevensys’ EyeCET platform, the first non-viral technology that allows reprogramming of the ciliary mus...
    Eyevensys is a private biotechnology company developing a novel approach in the treatment of major ophthalmic diseases. We create a bio therapeutics factory in the eye to allow safe local sustained production of therapeutic proteins, an approach that can address a wide range of ophthalmic diseases. Our approach is based on Eyevensys’ EyeCET platform, the first non-viral technology that allows reprogramming of the ciliary muscle cells for the production of well-known therapeutic proteins. Eyevensys’ lead product, EYS606 is being developed as a potential new treatment for non-infectious uveitis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EyevensysGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Eyevensys, 11 rue Watt – Bât B 75013 Paris
    Telephone
    Telephone
    +33 (0)1 84 79 10 60
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eyevensys.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/eyevensys
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eyevensys Recap Highlights from Investigator Meeting, Presentations at ARVO 2022
    Eyevensys Recap Highlights from Investigator Meeting, Presentations at ARVO 2022

    11 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220511005761/en

    BUSINESSWIRE
    11 May 2022
    Share Share
    Eyevensys upgrades ocular device to advance gene therapy trials
    Eyevensys upgrades ocular device to advance gene therapy trials

    27 Sep 2021

    // Andrea Park FIERCEBIOTECH

    https://www.fiercebiotech.com/medtech/eyevensys-taps-phillips-medisize-minnetronix-to-up-production-gene-therapy-device-for-eye

    Andrea Park FIERCEBIOTECH
    27 Sep 2021
    Share Share
    Eyevensys Raises $ 12 Million in Series B Plus Funding Round
    Eyevensys Raises $ 12 Million in Series B Plus Funding Round

    05 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210805005684/fr

    BUSINESSWIRE
    05 Aug 2021
    Share Share
    Eyevensys Raises $12M in a Series B Plus Funding Round
    Eyevensys Raises $12M in a Series B Plus Funding Round

    04 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210804005837/en

    BUSINESSWIRE
    04 Aug 2021
    Share Share
    Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment
    Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment

    05 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201005005058/en

    BUSINESSWIRE
    05 Oct 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search